<DOC>
	<DOCNO>NCT02213315</DOCNO>
	<brief_summary>A phase 1 randomize , double blind single-dose study evaluate PK immunogenicity single SC 100 150 mg dos mavrilimumab healthy adult Japanese subject .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled , Single-dose Study Evaluate PK , IM , Safety Japanese Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , parallel group , single-dose study evaluate PK , immunogenicity , safety mavrilimumab dose 100 150 mg healthy adult Japanese subject . The study conduct one site Europe subject randomize 5:5:2 ratio 100 , 150mg mavrilimumab placebo .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject Japanese ethnicity No evidence clinically significant respiratory disease Any condition , would interfere evaluation study drug safety subject . Subject know hypersensitivity component investigational product . History infection require hospitalization treatment IV antibiotic within 12 week screen , evidence clinically significant active infection . Subject history present condition malignancy . Subject history presence drug addiction ( urine test ) alcohol consumption ( breath test ) 21 ( male ) 14 ( female ) unit alcohol per week . Any blood donation significant loss blood within 56 day study initiation , Receipt live ( attenuate ) vaccine within 4 week screen study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy Volunteers , Rheumatoid Arthritis , mavrilimumab</keyword>
</DOC>